be visible on the BioBusiness market ISSN 2300-0228

Log in | Register

Pivotal announces participation in two clinical trials with a novel investigational immunotherapy drug to treat melanoma and lung cancer
Impressions from the visit to Wageningen, the specter of famine, CRISPR Cas9 to the rescue!
Reach out to potential partners and customers in the Danish-Swedish life science cluster, Medicon Valley
Central European Healthcare Expo (20-21.05.2020 Global Expo Warsaw)
The world of healthcare ...

All articles

Filters:

Show search box

2018-07-04

PIVOTAL and APRO partner to develop three Investigator Sponsored Trials in Genitourinary tu

PIVOTAL and APRO partner to develop three Investigator Sponsored Trials in Genitourinary tumours

PIVOTAL and APRO have today announced a close collaboration in three different oncology clinical trials to test new treatment strategies delivered in an innovative way. The three trials have been recently approved by the Competent Authorities and the corresponding Ethics Committees and have already ... Read more

Tags clinical trials , oncology , PIVOTAL , APRO

2015-02-04

Wortmannin as a new potential anticancer drug

Wortmannin as a new potential anticancer drug

Wortmannin sensitize the tumour cells for standard treatment with ethoposid and cisplatin, makes the treatment more effectiveness. What it means for the glioma patient? That there is potential new drug, which is effective in laboratory and kills glioma cells.... Read more

Tags cancer , glioblastoma , glioma , oncology , brain cancer